FDA warns Mylan on PR plant violations

The FDA has warned Mylan ($MYL) of "significant violations" of manufacturing rules at a plant in Caguas, Puerto Rico, where inspectors found the drugmaker failed to properly test for product uniformity and didn't fully investigate a batch failure. Report

Suggested Articles

With tens of millions of Americans tuned into Tuesday’s presidential debate, the race for a COVID-19 vaccine took center stage in a big way.

A $300M pandemic ad campaign may be falling apart as HHS employees push back, celebrities balk and agency brass push a rushed timeline, Politico says.

With a pack of drugmakers angling for COVID-19 vaccine approvals in the coming months, the task of global distribution is more important than ever. Wi